



## **Jaguar Health Announces that Ladenburg Thalmann is Hosting R&D Showcase Webinar About Cancer Therapy-related Diarrhea on September 29, 2021**

September 27, 2021

***Leading oncologists discuss importance of supportive care for cancer patients to address debilitating diarrhea resulting from cancer therapy***

***Virtual event 1:00 PM to 2:10 PM Eastern***

***Registration open now for financial and business community; Click [here](#) to register***

**SAN FRANCISCO, CA / ACCESSWIRE / September 27, 2021 /** Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Ladenburg Thalmann is hosting an R&D Showcase webinar about cancer therapy-related diarrhea (CTD) on September 29, 2021 from 1:00 p.m. to 2:10 p.m. Eastern. The virtual event, open to the financial and business community, will address the importance of supportive care for cancer patients to address the debilitating diarrhea that can be experienced because of cancer therapy.

Jaguar founder and CEO Lisa Conte and Pravin Chaturvedi, PhD, Jaguar's acting Chief Scientific Officer and Chair of Scientific Advisory Board, will participate in the virtual event, which will also include commentary from three distinguished oncologists: Lee Schwartzberg, MD, FACP, who is affiliated with the Renown Institute for Cancer; Eric Roeland, MD, FAAHPM, Assistant Professor, Oregon Health & Science University; and Andrew Davies, MB BS, MSc, MD, FRCP, President of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Director of the Development in Palliative Medicine, St. Luke's Cancer Centre/Royal Surrey County Hospital.

### **Participation Instructions for R&D Showcase**

Event is exclusively for investors, financial analysts, business media, and business development executives.

When: Wednesday, September 29, 2021 from 1:00 p.m. to 2:10 p.m. Eastern Time

Registration Link: [Click Here](#)

### **About Jaguar Health, Inc., Napo Pharmaceuticals, Inc. & Napo EU S.p.A.**

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Napo EU S.p.A., the wholly owned Italian subsidiary of Napo Pharmaceuticals, focuses on expanding crofelemer access in Europe and is the named target of Dragon SPAC S.p.A., which closed its financing in July 2021 for gross proceeds of approximately 8,830,000 euros from Jaguar.

For more information about Jaguar, please visit <https://jaguar.health>. For more information about Napo Pharmaceuticals, visit [www.napopharma.com](http://www.napopharma.com). For more information about Napo EU, visit [www.napoeu.com](http://www.napoeu.com).

### **Forward-Looking Statements**

Certain statements in this press release constitute "forward-looking statements." These include statements related to the expectation that Ladenburg Thalmann will host a CTD-focused R&D Showcase webinar on September 29, 2021. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Source: Jaguar Health, Inc.

### **Contact:**

Peter Hodge

Jaguar Health, Inc.

[phodge@jaguar.health](mailto:phodge@jaguar.health)

Jaguar-JAGX

**SOURCE:** Jaguar Health, Inc.

[accesswire.com](https://www.accesswire.com)

<https://www.accesswire.com/665461/Jaguar-Health-Announces-that-Ladenburg-Thalmann-is-Hosting-RD-Showcase-Webinar-About-Cancer-Therapy-related-Diarrhea-on-September-29-2021>